Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.68USD
11 Dec 2017
Change (% chg)

$-0.30 (-7.54%)
Prev Close
$3.98
Open
$4.00
Day's High
$4.00
Day's Low
$3.65
Volume
611,107
Avg. Vol
388,751
52-wk High
$4.47
52-wk Low
$1.94

Chart for

About

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $539.09
Shares Outstanding(Mil.): 146.49
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Rigel announces Q3 loss of $0.14 per share

* Rigel announces third quarter 2017 financial results and provides company update

Nov 07 2017

BRIEF-Rigel announces pricing of public offering of common stock

* Says public offering of 18.1 million common shares priced at $3.35 per share Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering

Oct 03 2017

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

Oct 03 2017

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

* Rigel provides update on FDA review of fostamatinib for ITP

Oct 02 2017

BRIEF-Rigel Q2 loss per share $0.16

* Rigel announces second quarter 2017 financial results and provides company update

Aug 01 2017

BRIEF-FDA accepts Rigel's NDA for Tavalisse

* FDA accepts Rigel's New Drug Application for Tavalisse™ (fostamatinib disodium) for the treatment of chronic ITP

Jun 19 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.00 0.00
Roche Holding Ltd. (ROG.S) CHF239.80 -0.80
Roche Holding Ltd. (RO.S) CHF243.00 -0.20
Merck & Co., Inc. (MRK.N) $56.34 +0.77
Sanofi SA (SASY.PA) €73.52 -0.06
AstraZeneca plc (AZN.L) 4,878.00 +1.00
Abbott Laboratories (ABT.N) $54.94 +0.30

Earnings vs. Estimates